TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Treating younger patients with TAVR increases risk of death
Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely.
Cardiologist demand is on the rise—can hospitals keep up?
Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind.
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.
New data put a spotlight on troubling TAVR trends
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, discussed how a proactive treatment strategy for patients with asymptomatic AS can lead to better outcomes and improvements in quality of life.

TAVR stands tall as ‘the dominant form of aortic valve replacement,’ specialty groups declare

Specialists from the American College of Cardiology and Society of Thoracic Surgeons explored data from more than 276,000 patients who have undergone a TAVR procedure in the last nine years.

November 16, 2020

Wait times for TAVR, SAVR patients are getting longer and longer

The study’s authors tracked data from more than 22,000 patients with severe aortic stenosis.

November 12, 2020

Among TAVR patients with AFib, DOACs lead to better survival rates than vitamin K antagonists

However, the two treatment options were associated with similar rates of long-term bleeding and ischemic events.

November 6, 2020

New meta-analysis compares early TAVR outcomes for Sapien 3, Evolut valves—and spots some key differences

The new study focused on the early outcomes of more than 24,000 patients who participated in a total of nine different studies.

November 3, 2020

Embolic protection devices fail to limit death or stroke among TAVR patients

The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials.

October 26, 2020

American College of Cardiology shares new guidance on TAVR-related conduction disturbances

The new guidance was designed to help clinicians provide high-quality care before, during and after TAVR procedures.

October 21, 2020

Medtronic announces 2 new TAVR studies, including a head-to-head comparison of Evolut Pro and Sapien 3

A new feasibility study focused on additional patient populations is also in the works.

October 14, 2020

Valve durability after 5 years: Sapien 3 TAVR outcomes comparable to SAVR

The Sapien 3 prosthesis continues to impress, though researchers must continue to monitor its performance as time goes on.

October 13, 2020

TAVR

Treating younger patients with TAVR increases risk of death

Cardiologist demand is on the rise—can hospitals keep up?

Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years

New data put a spotlight on troubling TAVR trends

Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes